BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34342289)

  • 21. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
    Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Ko EM; Bekelman JE; Hicks-Courant K; Brensinger CM; Kanter GP
    Gynecol Oncol; 2022 Feb; 164(2):295-303. PubMed ID: 34949437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.
    Schrag D; Earle C; Xu F; Panageas KS; Yabroff KR; Bristow RE; Trimble EL; Warren JL
    J Natl Cancer Inst; 2006 Feb; 98(3):163-71. PubMed ID: 16449676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass.
    Goff BA; Miller JW; Matthews B; Trivers KF; Andrilla CH; Lishner DM; Baldwin LM
    Obstet Gynecol; 2011 Oct; 118(4):854-62. PubMed ID: 21934449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-reducing Bilateral Salpingo-oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    Newcomb LK; Toal CT; Rindos NB; Wang L; Mansuria SM
    J Minim Invasive Gynecol; 2020; 27(7):1511-1515. PubMed ID: 31927044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
    Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
    Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer.
    Facer B; Wang F; Grijalva CG; Alvarez RD; Shu XO
    Am J Obstet Gynecol; 2020 May; 222(5):474.e1-474.e12. PubMed ID: 31715149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of geographic variations in treatment on outcomes in ovarian cancer.
    Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
    Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of contemporary trends in access to high-volume ovarian cancer surgical care.
    Bristow RE; Puri I; Diaz-Montes TP; Giuntoli RL; Armstrong DK
    Ann Surg Oncol; 2009 Dec; 16(12):3422-30. PubMed ID: 19711131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
    Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
    Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
    J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
    J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Centralization of ovarian cancer surgery: do patients benefit?
    Ghaemmaghami F; Hassanzadeh M; Karimi-Zarchi M; Modari-Gilani M; Behtash A; Mousavi N
    Eur J Gynaecol Oncol; 2010; 31(4):429-33. PubMed ID: 20882887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely.
    Nishikimi K; Tate S; Kato K; Matsuoka A; Shozu M
    J Gynecol Oncol; 2020 Jan; 31(1):e3. PubMed ID: 31788993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.